show a benefit from somatic gene therapy efficacy studies will be prolonged and expensive, and will require large numbers of patients.
With respect to gene therapy for a, antitrypsin deficiency, the safety aspects are critical because the natural history of this condition is largely unknown, and many patients appear to escape seriously disabling disease, particularly if they do not smoke.'0 In addition, sufficient quantities of a, antitrypsin must be produced by lung cells in order to slow the rate of progression of lung disease. Intratracheal administration of recombinant adenoviral vectors may have greater potential in the management of cystic fibrosis, which is a disease of the airways.
In summary, pioneering steps have been taken towards somatic gene therapy for two of the most prevalent serious hereditary pulmonary conditions of white people. Although the rate of progress in rapidly developing fields such as recombinant DNA technology is difficult to predict, clinical applications will probably be in the distant future.
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